Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Bayer AG
  6. News
  7. Summary
    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 10/18 07:46:28 am
46.928 EUR   -2.00%
02:51aBAYER AG : Receives a Buy rating from JP Morgan
MD
02:10aBAYER : Belmora Seeks SCOTUS Review For The Second Time In Its Cross-Border Trademark Battle With Bayer Over FLANAX
AQ
10/15CureVac Shares Down 12%
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bayer : extends clinical development program for finerenone with Phase III study in patients with non-diabetic chronic kidney disease

09/20/2021 | 08:02am EDT
SPECIALIZED PRESS
Monday - September 20, 2021
Bitte JavaScript aktivieren / Please enable JavaScript



About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.com.

Find more information at https://pharma.bayer.com/
Follow us on Facebook: http://www.facebook.com/bayer
Follow us on Twitter: @BayerPharma

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Disclaimer

Bayer AG published this content on 20 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 September 2021 12:01:09 UTC.


© Publicnow 2021
All news about BAYER AG
02:51aBAYER AG : Receives a Buy rating from JP Morgan
MD
02:10aBAYER : Belmora Seeks SCOTUS Review For The Second Time In Its Cross-Border Trademark Batt..
AQ
10/15CureVac Shares Down 12%
DJ
10/15BAYER AG : Gets a Buy rating from DZ Bank
MD
10/13BAYER CROPSCIENCE : to Sell Traded Seeds Business for Over $8 Million
MT
10/13BAYER AG : Bernstein maintains a Buy rating
MD
10/12VC DAILY : Is It All or Nothing for Founders?
DJ
10/11BAYER AG : Buy rating from UBS
MD
10/08Bayer blasts 'unscientific' rejection by Mexican regulator of GMO corn permit
RE
10/08BLACKROCK : Blackstone, Carlyle Reportedly Among Suitors for German-Listed Bayer's Pest Co..
MT
More news
Analyst Recommendations on BAYER AG
More recommendations
Financials
Sales 2021 42 602 M 49 353 M 49 353 M
Net income 2021 860 M 997 M 997 M
Net Debt 2021 39 369 M 45 608 M 45 608 M
P/E ratio 2021 28,4x
Yield 2021 4,25%
Capitalization 47 043 M 54 575 M 54 498 M
EV / Sales 2021 2,03x
EV / Sales 2022 1,93x
Nbr of Employees 99 439
Free-Float 100,0%
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | BAYN | DE000BAY0017 | MarketScreener
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 47,89 €
Average target price 61,32 €
Spread / Average Target 28,1%
EPS Revisions
Managers and Directors
Werner Baumann Chairman-Management Board & CEO
Wolfgang U. Nickl Chief Financial Officer
Norbert Winkeljohann Chairman-Supervisory Board
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BAYER AG-0.56%54 575
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.12.71%232 621
ELI LILLY AND COMPANY40.89%215 657